

PROSTATE CANCER RESEARCH PROGRAM



MISSION: Fund research that will eliminate death and suffering from prostate cancer and enhance the well-being of Service Members and their Families, Veterans and all the patients and caregivers who are experiencing the impact of the disease.

Congressional Appropriations

FY97-FY25:

\$2.445B total

SCOPE OF THE PROBLEM

Estimated **313,750** new diagnoses and **35,770** deaths from prostate cancer in 2025¹




From 2017 to 2021, 70% of cases found localized; **22%** found **beyond the primary site**²



Available treatments can result in **urinary, bowel and sexual dysfunction**³

High-risk populations continue to show **increased incidence and mortality**⁴






“When I had a prostate cancer recurrence 18 years ago, I knew that my disease was terminal and that there were only three FDA-approved drugs that could possibly extend my life and help maintain a decent quality of life, as well as a few radio-pharmaceutical types of drugs that would only make me feel even sicker. I also knew that these drugs would not work forever. Thanks to cutting-edge research in prostate cancer, much of which has been led by the innovative nature of the PCRp, I remain, 18 years later, alive and healthy, being a productive member of my community. Not only am I still contributing to society, I also have a constantly growing list of available new drugs and treatments which provide me with optimism about my future.”

*Joel Nowak, Cancer ABCs, Inc.,
FY14-FY24 Programmatic Panel Member*

RELEVANCE TO MILITARY HEALTH

MHS Medical Encounters for Prostate Cancer, 2013-2022⁵

	 Average Patients per Year	 Out-Patient Encounters	 Hospital Bed Days
Service Members	227	12,556	965
Other DOD Beneficiaries	72,617	3.54 million	108,689

PROGRAM PRIORITIES

The PCRp remains focused on addressing the knowledge, research and clinical gaps that continue to make prostate cancer a global health issue

- Improve quality of life for those impacted by prostate cancer
- Define the biology of progression to lethal prostate cancer
- Develop new or improved therapies for lethal prostate cancer
- Improve access to optimal care for all patients with prostate cancer

¹ American Cancer Society, Cancer Facts & Figures, 2024.

² Centers for Disease Control and Prevention. Prostate Cancer Incidence by Age and Stage at Diagnosis, United States—2001–2019. USCS Data Brief, no. 34. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2023.

³ American Society of Clinical Oncology. 2023. Prostate Cancer: Types of Treatment 2022. Alexandria, VA. December 14, 2022.

⁴ Giaquinto AN, et al. *CA Cancer J Clin* 72, no.3, 2022:202-229.


⁵ Military Health System (MHS) data from the Defense Medical Surveillance System, 2012-2022. The Armed Forces Health Surveillance Division, Defense Health Agency (DHA), Silver Spring, Maryland, January 2024.



For more information, visit: <https://cdmrp.health.mil/pcrp>

PROGRAM IMPACT AND OUTCOMES

Prostate Cancer Clinical Trials Consortium



12 Therapies Approved by FDA

177Lu-PSMA-617; Pluvicto®		Darolutamide; Nubeqa®		Olaparib; Lynparza®	
Abiraterone acetate; Zytiga®, Yonsa®		Degarelix; Firmagon®		Rucaparib; Rubraca®	
Apalutamide; Erleada®		Enzalutamide; Xtandi®		Sipuleucel-T; Provenge®	
Cabazitaxel; Jevtana®		Niraparib; Zejula®		Talazoparib; Talzenna®	

PERSONALIZED IMMUNOTHERAPY

PCRP-funded preclinical research led to a clinical trial for metastatic castration-resistant prostate cancer.

- Treatment with **enzalutamide plus modified T cells** demonstrated improved outcomes in a preclinical prostate cancer model
- Following the PCRP award, this treatment approach advanced to a **phase 1 clinical trial** to test safety and efficacy



IMPLEMENTATION SCIENCE

In FY24, the PCRP offered a unique award mechanism to accelerate advancements for patient care into widespread acceptance and routine practice.

Goals of the PCRP Implementation Science Award

- **Accelerate** the uptake of evidence-based practice and research into regular use in prostate cancer clinical settings
- **Bridge** gaps among research, clinical practice and health policy
- **Improve** patient outreach, outcomes and effectiveness of care



Point of Contact: CDMRP Public Affairs
dha.detrick.cdmpm.mbx.public-affairs@health.mil